×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Transient Ischemic Attack Market Size

ID: MRFR/Pharma/3590-CR
226 Pages
Rahul Gotadki
July 2019

Transient Ischemic Attack Market Research Report Information by Diagnosis (Imaging Techniques), Treatment (Surgery and Drugs), Age Groups (0–18 years and above), End-User and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Transient Ischemic Attack Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Transient Ischemic Attack Size

Transient Ischemic Attack Market Growth Projections and Opportunities

The transient ischemic attack (TIA) market is a significant aspect of healthcare, focusing on the prevention, diagnosis, and treatment of temporary disruptions in blood flow to the brain. Often referred to as "mini-strokes," TIAs are warning signs of potential strokes and require prompt medical attention to prevent more severe neurological damage. This market segment is vital due to the serious consequences associated with TIAs, including an increased risk of subsequent strokes, cognitive impairment, and disability. As awareness of TIAs grows among healthcare professionals and the general population, there is a growing demand for effective strategies to identify and manage these transient events.

Key players in the TIA market include pharmaceutical companies, medical device manufacturers, diagnostic imaging providers, and healthcare facilities specializing in stroke care. Pharmaceutical interventions play a crucial role in preventing recurrent TIAs and strokes by targeting underlying risk factors such as hypertension, hyperlipidemia, and atrial fibrillation. Medications such as antiplatelet agents (e.g., aspirin, clopidogrel), anticoagulants, statins, and blood pressure-lowering drugs are commonly prescribed to reduce the risk of clot formation, improve blood flow, and stabilize atherosclerotic plaques in the arteries supplying the brain.

In addition to pharmaceutical interventions, medical devices and diagnostic tools play a crucial role in the TIA market by enabling healthcare providers to accurately diagnose TIAs, assess stroke risk, and guide treatment decisions. Advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and carotid ultrasound are used to visualize blood flow in the brain and identify potential causes of TIA symptoms, such as arterial stenosis or emboli. These imaging techniques help clinicians differentiate between TIAs and other neurological conditions, allowing for timely intervention and risk stratification.

Another important aspect of the TIA market is rehabilitation and secondary prevention strategies aimed at reducing the risk of recurrent TIAs and strokes. Rehabilitation programs may include physical therapy, occupational therapy, speech therapy, and cognitive rehabilitation to address deficits in motor function, activities of daily living, communication, and cognitive abilities. Lifestyle modifications, such as smoking cessation, dietary changes, exercise, and weight management, are also emphasized to control modifiable risk factors and improve overall cardiovascular health.

The TIA market is influenced by various factors, including demographic trends, epidemiological patterns, healthcare policies, and technological advancements. With an aging population and a growing prevalence of risk factors such as obesity, diabetes, and hypertension, the burden of TIAs and strokes is expected to increase globally. As a result, there is a growing emphasis on preventive measures, early detection, and comprehensive stroke care to reduce the societal and economic impact of these neurological events.

Technological innovations are driving advancements in the diagnosis and treatment of TIAs, with emerging trends such as telemedicine, artificial intelligence (AI), and remote monitoring showing promise in improving access to care and optimizing treatment outcomes. Telestroke programs enable remote consultation and decision-making between stroke specialists and healthcare providers in underserved areas, facilitating timely administration of thrombolytic therapy and other acute interventions. AI algorithms are being developed to analyze medical imaging data and assist radiologists in detecting subtle abnormalities indicative of TIAs, allowing for faster and more accurate diagnoses.

Transient Ischemic Attack Market Size Graph
Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

At what CAGR is the global transient ischemic attack market projected to grow in the forecast period (2024-2032)?

Transient ischemic attack market projected to grow at approximately 9.24% CAGR during the assessment period (2024-2032).

How much is the global transient ischemic attack market worth in the future?

The valuation of the global transient ischemic attack market is estimated to increase to USD 0.29 Billion by the end of 2032.

What are the major tailwinds pushing the growth of the global transient ischemic attack market?

Rising need for better treatment due to the increasing prevalence of neurological disorders and increasing R&D investments in biotechnology and pharmaceutical sectors are major tailwinds pushing the growth of the global transient ischemic attack market.

Which region holds the largest share in the global transient ischemic attack market?

North America holds the largest share in the global transient ischemic attack market, followed by Europe and the Asia Pacific, respectively.

Who are the top players in the global transient ischemic attack market?

EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), LivaNova PLC (U.K), Cyberonics, Inc. (US), NeuroMetrix, Inc.(U.S.), Boston Scientific Corporation (US), Inspire Medical Systems Inc.(U.S.), Electrical Geodesics Inc. (U.S.), ImThera Medical (U.S.), Nihon Kohden Corporation (Japan), Esaote (Italy), Masimo Corporation (U.S.), and Hologic (U.S.), are some of the top players operating in the global transient ischemic attack market.

Market Summary

The Global Transient Ischemic Attack Market is projected to grow from 0.12 USD Billion in 2024 to 0.38 USD Billion by 2035.

Key Market Trends & Highlights

Transient Ischemic Attack Market Key Trends and Highlights

  • The market is expected to experience a compound annual growth rate (CAGR) of 11.0% from 2025 to 2035.
  • By 2035, the market valuation is anticipated to reach 0.38 USD Billion, indicating robust growth potential.
  • In 2024, the market is valued at 0.12 USD Billion, reflecting the current demand for TIA management solutions.
  • Growing adoption of advanced diagnostic technologies due to increasing awareness of transient ischemic attacks is a major market driver.

Market Size & Forecast

2024 Market Size 0.12 (USD Billion)
2035 Market Size 0.38 (USD Billion)
CAGR (2025-2035) 11.0%
Largest Regional Market Share in 2024 latin_america)

Major Players

Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), Boehringer Ingelheim GmbH (Germany)

Market Trends

Transient Ischemic Attack Market Market Drivers

Aging Population

The demographic shift towards an aging population is a crucial factor driving the Global Transient Ischemic Attack Market Industry. As individuals age, the risk of cerebrovascular diseases, including TIAs, escalates. The United Nations projects that by 2030, the global population aged 60 years and older will reach 1.4 billion, creating a larger cohort susceptible to TIAs. This demographic trend necessitates enhanced healthcare services and interventions tailored to older adults, thereby fostering market expansion. The increasing burden of TIAs among the elderly population underscores the importance of developing targeted therapies and preventive measures.

Rising Incidence of Stroke

The increasing prevalence of stroke globally is a pivotal driver for the Global Transient Ischemic Attack Market Industry. As per recent health statistics, stroke remains one of the leading causes of morbidity and mortality worldwide. The World Health Organization indicates that approximately 15 million people suffer from stroke annually, with a significant portion experiencing transient ischemic attacks as precursors. This alarming trend underscores the necessity for enhanced diagnostic and therapeutic interventions, thereby propelling market growth. The Global Transient Ischemic Attack Market is projected to reach 0.12 USD Billion in 2024, reflecting the urgent need for effective management strategies.

Market Trends and Projections

The Global Transient Ischemic Attack Market Industry is witnessing notable trends that indicate a robust growth trajectory. Projections suggest that the market will expand from 0.12 USD Billion in 2024 to 0.38 USD Billion by 2035, reflecting a compound annual growth rate of 11.0% from 2025 to 2035. This growth is driven by various factors, including advancements in medical technology, increased awareness, and an aging population. The market dynamics are influenced by the evolving healthcare landscape, necessitating continuous adaptation by stakeholders to meet the demands of TIA management.

Regulatory Support and Funding

Government initiatives and regulatory support play a vital role in shaping the Global Transient Ischemic Attack Market Industry. Various health authorities are implementing policies aimed at improving stroke care and funding research for innovative treatments. For example, the National Institutes of Health in the United States allocates substantial resources to stroke research, which indirectly benefits TIA management. Such funding encourages the development of new therapies and technologies, thereby enhancing patient care. This supportive regulatory environment is expected to facilitate market growth, as stakeholders are more inclined to invest in TIA-related innovations.

Increased Awareness and Education

Growing awareness regarding transient ischemic attacks and their implications is significantly influencing the Global Transient Ischemic Attack Market Industry. Public health campaigns and educational initiatives by health organizations aim to inform individuals about the symptoms and risks associated with TIAs. This heightened awareness encourages early medical intervention, which is essential for preventing subsequent strokes. As a result, healthcare systems are increasingly prioritizing TIA management, leading to a surge in demand for related services and products. The market is expected to experience a compound annual growth rate of 11.0% from 2025 to 2035, driven by these educational efforts.

Advancements in Medical Technology

Technological innovations in medical devices and diagnostic tools are transforming the landscape of the Global Transient Ischemic Attack Market Industry. The advent of portable imaging technologies and telemedicine solutions facilitates timely diagnosis and treatment, which is crucial for TIA patients. For instance, advanced MRI techniques enable rapid identification of ischemic episodes, thereby improving patient outcomes. Furthermore, the integration of artificial intelligence in predictive analytics is enhancing risk stratification for TIA patients. These advancements not only improve clinical efficacy but also contribute to the anticipated market growth, with projections indicating a rise to 0.38 USD Billion by 2035.

Market Segment Insights

Regional Insights

Key Companies in the Transient Ischemic Attack Market market include

Industry Developments

Future Outlook

Transient Ischemic Attack Market Future Outlook

The Global Transient Ischemic Attack Market is projected to grow at an 11.0% CAGR from 2024 to 2035, driven by advancements in diagnostics, increasing awareness, and enhanced treatment options.

New opportunities lie in:

  • Develop AI-driven diagnostic tools to improve early detection of TIAs.
  • Invest in telehealth solutions for remote monitoring and patient management.
  • Create targeted therapies focusing on high-risk populations to enhance treatment efficacy.

By 2035, the market is expected to achieve substantial growth, reflecting advancements in treatment and increased patient engagement.

Market Segmentation

Market Segmentation

Transient Ischemic Attack Market, by Region
  • Americas
  • North America
  • US
  • Canada
  • Latin America
  • Europe
  • Western Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Middle East
  • Africa
Transient Ischemic Attack Market, by End-User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Research Laboratories
Transient Ischemic Attack Market, by Diagnosis
  • Imaging Techniques
  • Computed Tomography (CT) scan
  • Carotid Duplex Scanning
  • Magnetic Resonance Imaging
  • Echocardiography            
Transient Ischemic Attack Market, by Treatment
  • Surgery
  • Drugs
  • Antithrombotic agents
  • Antiplatelets
  • Clopidogrel
  • Aspirin
  • Heparins
  • ENOXAPARIN
  • DALTEPARIN
  • Fibrinolytics
  • Tenecteplase
Transient Ischemic Attack Market, by Age Groups
  • 0–18 years
  • 19–40 years (Millennial)
  • 41–60 years
  • 60+ years

Report Scope

Attribute/Metric Details
Market Size 2030  USD 0.29 Billion 2032
Compound Annual Growth Rate (CAGR) 9.34% 2032
Base Year 2021
Market Forecast Period 2024-2032
Historical Data 2018 - 2021
Market Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Product, technology, application, and end-users.
Geographies Covered Americas, Europe, Asia Pacific and the Middle East and Africa
Countries Covered China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific
Key Companies Profiled Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), and Boehringer Ingelheim GmbH (Germany).
Key Market Opportunities Key market opportunities for the Transient Ischemic Attack market include the development of advanced diagnostic tools, innovative treatment options, and personalized medicine approaches to improve early detection and patient outcomes.
Key Market Dynamics   The key market dynamics for the transient ischemic attack (TIA) market include increasing incidence rates, advances in diagnostic and therapeutic technologies, growing awareness and early intervention, and substantial investment in research and development.

FAQs

At what CAGR is the global transient ischemic attack market projected to grow in the forecast period (2024-2032)?

Transient ischemic attack market projected to grow at approximately 9.24% CAGR during the assessment period (2024-2032).

How much is the global transient ischemic attack market worth in the future?

The valuation of the global transient ischemic attack market is estimated to increase to USD 0.29 Billion by the end of 2032.

What are the major tailwinds pushing the growth of the global transient ischemic attack market?

Rising need for better treatment due to the increasing prevalence of neurological disorders and increasing R&D investments in biotechnology and pharmaceutical sectors are major tailwinds pushing the growth of the global transient ischemic attack market.

Which region holds the largest share in the global transient ischemic attack market?

North America holds the largest share in the global transient ischemic attack market, followed by Europe and the Asia Pacific, respectively.

Who are the top players in the global transient ischemic attack market?

EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), LivaNova PLC (U.K), Cyberonics, Inc. (US), NeuroMetrix, Inc.(U.S.), Boston Scientific Corporation (US), Inspire Medical Systems Inc.(U.S.), Electrical Geodesics Inc. (U.S.), ImThera Medical (U.S.), Nihon Kohden Corporation (Japan), Esaote (Italy), Masimo Corporation (U.S.), and Hologic (U.S.), are some of the top players operating in the global transient ischemic attack market.

  1. Report Prologue
  2. Executive Summary
  3. Market Introduction
    1. Definition 26
    2. Scope Of Study
    3. List Of Assumptions 26
    4. Market Structure 27
  4. Research Methodology
    1. Research Process 29
    2. Primary
    3. Research 30
    4. Secondary Research 31
    5. Market Size Estimation
    6. Forecast Model 32
  5. Market Dynamics
    1. Introduction 34
    2. Drivers 35
      1. Increasing Preference
      2. Rising Prevalence Of Chronic
      3. Improvement In Reimbursement Scenario 37
      4. Rising Geriatric Population 38
    3. For Minimally Invasive Procedures 35
    4. Disorders 36
    5. Restraints 39
      1. Lack Of Skilled Physicians
    6. Rising Treatment Cost And Hospital Stay 39
    7. Opportunities 41
      1. New Advancements In Catheterization
      2. Guide Wire Assisted Surgery In Elderly Population 41
    8. Devices 41
    9. Mega Trends 41
      1. Telemedicine 41
    10. Macroeconomic
    11. Indicators 41
    12. Technology Trends & Assessment 42
    13. Market Factor Analysis
    14. Porter’s Five Forces Model 44
      1. Threat Of New Entrants 44
      2. Bargaining Power Of Suppliers
      3. Threat Of Substitutes 45
      4. Bargaining Power Of
      5. Intensity Of Rivalry 45
    15. Buyers 45
    16. Supply Chain Analysis
      1. Research &Development 46
      2. Manufacturing
      3. Distribution 46
      4. Marketing & Sales 47
      5. Post-Sales Monitoring 47
    17. Demand & Supply: Gap Analysis
    18. Pricing Analysis 47
    19. Investment Feasibility Analysis
  6. Global Transient Ischemic Attack Market, By Diagnosis
    1. Introduction 49
    2. Imaging Techniques 49
      1. Computed Tomography
      2. Carotid Duplex Scanning 51
      3. Magnetic
      4. Echocardiography 52
    3. (CT) Scan 51
    4. Resonance Imaging 52
  7. Global Transient
  8. Ischemic Attack Market, By Treatment
    1. Introduction 54
    2. Surgery 54
    3. Drugs 54
      1. Surgery 55
    4. Drugs 56
    5. Heparins 57
    6. Alteplase 59
    7. Prazosin 60
  9. Global Transient Ischemic
  10. Attack Market, By Age Groups
    1. Introduction 62
    2. 0–18
    3. Years 62
    4. 19–40 Years (Millennial) 62
    5. 41–60
    6. Years 62
    7. 60+ Years 63
      1. 0-18 Years 64
      2. 41-60 Years 65
      3. 60+ Years 65
    8. 19-40 Years 65
  11. Global Transient Ischemic Attack Market, By End-User
    1. Introduction 67
    2. Hospitals & Clinics 67
    3. Diagnostic
    4. Centers 67
    5. Research Laboratories 68
      1. Hospitals
      2. Diagnostic Centers 70
      3. Research Laboratories
  12. Global Transient Ischemic Attack Market, By Region
    1. Introduction 72
    2. Americas 73
      1. North America 78
      2. South America
    3.  
    4. Europe 94
      1. Western Europe
      2. Eastern Europe 127
      3. Asia Pacific 132
      4. Japan 136
      5. China 140
      6. India 144
      7. Australia
      8. Republic Of Korea 152
      9. Rest Of Asia Pacific
    5. U.K. 111
    6. Rest Of Western Europe 123
    7. Asia Pacific 131
    8. The Middle East & Africa 160
      1. Middle East
      2. United Arab Emirates 164
      3. Saudi
      4. Rest Of Middle East & Africa 172
    9. And Africa 161
    10. Arabia 168
    11. Competitive Landscape
    12. Company Market Share Analysis 177
      1. Introduction 177
    13. Company Share Analysis 178
    14. Recent Developments, 2013–2018 179
  13. Company Profiles
    1. Koninklijke Philips N.V. 184
      1. Company Overview 184
      2. Financial Overview 184
      3. Products Offering 185
      4. Key Developments 185
      5. SWOT Analysis 185
    2. Key Strategy 186
    3. Stryker Corporation 187
      1. Company
      2. Financial Overview 187
      3. Products
      4. Key Developments 188
      5. SWOT Analysis
      6. Key Strategy 189
    4. Overview 187
    5. Offering 188
    6. Johnson & Johnson Services
      1. Company Overview 190
      2. Financial Overview
      3. Products Offering 191
      4. Key Developments 191
      5. SWOT Analysis 192
      6. Key Strategy 192
      7. Company Overview 193
      8. Financial Overview 193
      9. Products Offering 194
      10. Key Developments 195
      11. SWOT Analysis 195
    7. Inc. 190
    8. Boston Scientific Corporation 193
    9. Key Strategy 195
    10. Sanofi 196
      1. Company Overview 196
      2. Financial Overview 196
      3. Products Offering 197
      4. Key Developments 197
      5. SWOT Analysis 197
      6. Key Strategy 197
    11. Bayer AG 198
      1. Company
      2. Financial Overview 198
      3. Products
      4. Key Developments 199
      5. SWOT Analysis
      6. Key Strategy 199
    12. Overview 198
    13. Offering 199
    14. Pfizer Inc. 200
      1. Company Overview 200
      2. Financial Overview 200
      3. Products Offering 201
      4. Key Developments 201
      5. Key Strategy 201
    15. SWOT Analysis 201
    16. Siemens AG
      1. Company Overview 202
      2. Financial Overview
      3. Products Offering 203
      4. Key Developments 203
      5. SWOT Analysis 203
      6. Key Strategy 203
      7. Company Overview 204
      8. Products Offering 205
      9. SWOT Analysis 205
      10. Key Strategy
    17. F. Hoffmann-La Roche AG 204
    18. Financial Overview 204
    19. Key Developments 205
    20. GE Healthcare 206
      1. Company Overview 206
      2. Financial Overview 206
      3. Products Offering 207
      4. Key Developments 207
      5. SWOT Analysis 207
      6. Key Strategy 207
    21. Penumbra, Inc. 208
      1. Financial Overview 208
      2. Key Developments 209
      3. Key Strategy 210
    22. Company Overview 208
    23. Products Offering 209
    24. SWOT Analysis 209
    25. Medtronic
      1. Company Overview 211
      2. Financial Overview
      3. Products Offering 212
      4. Key Developments
      5. SWOT Analysis 212
      6. Key Strategy 213
    26. PLC 211
    27. Abbott Laboratories 214
      1. Company Overview 214
      2. Financial Overview 214
      3. Products Offering 215
      4. Key Developments 215
      5. SWOT Analysis 216
      6. Key Strategy 216
    28. Merck & Co., Inc. 217
      1. Financial Overview 217
      2. Key Developments 218
      3. Key Strategy 218
    29. Company Overview 217
    30. Products Offering 218
    31. SWOT Analysis 218
    32. Boehringer
      1. Company Overview 219
      2. Financial
      3. Products Offering 220
      4. Key Developments
      5. SWOT Analysis 220
      6. Key Strategy 220
    33. Ingelheim GmbH 219
    34. Overview 219
  14. Conclusion
    1. Key Findings 222
      1. CEO’s
      2. Unmet Needs 222
      3. Key Companies
      4. Prediction 222
    2. Viewpoint 222
    3. To Watch 222
  15. Appendix
    1. Discussion Blue Print 224
    2. References 225
  16. List Of Tables
  17. MARKET SYNOPSIS 24
  18. LIST OF ASSUMPTIONS 26
  19. PRIMARY INTERVIEWS 30
  20. GLOBAL TRANSIENT ISCHEMIC
  21. ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 50
    1. TABLE 5
  22. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUES, 2020–2027
    1. (USD MILLION) 50
  23. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. IMAGING TECHNIQUES, BY COMPUTED TOMOGRAPHY (CT) SCAN,
    2. (USD MILLION) 51
  24. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. IMAGING TECHNIQUES, BY CAROTID DUPLEX SCANNING,
    2. MILLION) 51
  25. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING
    1. TECHNIQUES, BY MAGNETIC RESONANCE IMAGING,
  26. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES,
    1. BY ECHOCARDIOGRAPHY,
    2. TABLE
  27. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY TREATMENT, 2020–2027 (USD MILLION)
  28. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY
    1. SURGERY, 2020–2027 (USD MILLION) 55
  29. GLOBAL TRANSIENT ISCHEMIC
  30. ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 56
  31. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUG, BY ANTITHROMBOTIC AGENTS,
  32. GLOBAL TRANSIENT ISCHEMIC ATTACK
  33. MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    1. MILLION) 56
  34. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS,
    1. BY CLOPIDOGREL, 2020–2027 (USD MILLION) 57
  35. GLOBAL TRANSIENT
  36. ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY ASPIRIN, 2020–2027 (USD MILLION)
  37. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 57
  38. GLOBAL
  39. TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY ENOXAPARIN, 2020–2027 (USD
    1. MILLION) 58
  40. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS,
    1. BY DALTEPARIN, 2020–2027 (USD MILLION) 58
  41. GLOBAL TRANSIENT
  42. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    1. (USD MILLION) 58
  43. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. FIBRINOLYTICS, BY TENECTEPLASE, 2020–2027 (USD MILLION) 59
    2. TABLE
  44. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY ALTEPLASE 2020–2027
    1. (USD MILLION) 59
  45. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 59
    2. TABLE
  46. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY PRAZOSIN,
  47. GLOBAL TRANSIENT ISCHEMIC
  48. ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY MOXONIDINE,
    1. (USD MILLION) 60
  49. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY
    1. AGE GROUPS, 2020–2027 (USD MILLION) 63
  50. GLOBAL TRANSIENT
  51. ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 0-18 YEARS, 2020–2027 (USD MILLION)
  52. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY
    1. 19-40 YEARS, 2020–2027 (USD MILLION) 65
  53. GLOBAL TRANSIENT
  54. ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 41-60 YEARS, 2020–2027 (USD MILLION)
  55. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY
    1. 60+ YEARS, 2020–2027 (USD MILLION) 65
  56. GLOBAL TRANSIENT
  57. ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 68
    1. TABLE
  58. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HOSPITALS, BY REGION, 2020–2027
    1. (USD MILLION) 69
  59. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 70
    2. TABLE
  60. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR RESEARCH LABORATORIES, BY REGION,
  61. GLOBAL TRANSIENT ISCHEMIC ATTACK
  62. MARKET, BY REGION, 2020–2027 (USD MILLION) 72
  63. AMERICAS
  64. TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 73
  65. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027
    1. (USD MILLION) 74
  66. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 74
    2. TABLE
  67. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD
    1. MILLION) 74
  68. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT,
    1. BY DRUGS, 2020–2027 (USD MILLION) 75
  69. AMERICAS TRANSIENT
  70. ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD
    1. MILLION) 75
  71. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY ANTIPLATELETS,
    2. TABLE
  72. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  73. AMERICAS TRANSIENT
  74. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    1. (USD MILLION) 76
  75. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 76
    2. TABLE
  76. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD
    1. MILLION) 77
  77. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER,
  78. NORTH AMERICA: TRANSIENT ISCHEMIC
  79. ATTACK MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78
  80. NORTH
  81. AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION)
  82. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS,
    1. BY IMAGING TECHNIQUE,
    2. TABLE
  83. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027
    1. (USD MILLION) 79
  84. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET
    1. FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 79
  85. NORTH
  86. AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
  87. NORTH AMERICA TRANSIENT
  88. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    1. (USD MILLION) 80
  89. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET
    1. FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  90. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY FIBRINOLYTICS,
    2. TABLE
  91. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE
    1. AGENTS,
  92. NORTH AMERICA
  93. TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 81
  94. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027
    1. (USD MILLION) 82
  95. U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS,
  96. U.S. TRANSIENT ISCHEMIC ATTACK
  97. MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 82
  98. U.S. TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027
    1. (USD MILLION) 83
  99. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT,
    1. BY DRUGS, 2020–2027 (USD MILLION) 83
  100. U.S. TRANSIENT ISCHEMIC
  101. ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION)
  102. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY ANTIPLATELETS,
    2. TABLE
  103. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  104. U.S. TRANSIENT ISCHEMIC ATTACK
  105. MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    1. MILLION) 84
  106. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS,
    1. BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 85
    2. TABLE 69
  107. U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION)
  108. U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027
    1. (USD MILLION) 85
  109. CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY
    1. DIAGNOSIS, 2020–2027 (USD MILLION) 86
  110. CANADA TRANSIENT
  111. ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD
    1. MILLION) 86
  112. CANADA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,,
  113. CANADA TRANSIENT ISCHEMIC ATTACK
  114. MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 87
    1. TABLE
  115. CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
  116. CANADA TRANSIENT ISCHEMIC ATTACK
  117. MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    1. MILLION) 87
  118. CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 88
  119. CANADA
  120. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  121. CANADA TRANSIENT ISCHEMIC
  122. ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION)
  123. CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027
    1. (USD MILLION) 89
  124. CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY
    1. END-USER, 2020–2027 (USD MILLION) 89
  125. SOUTH AMERICA TRANSIENT
  126. ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 90
  127. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING
    1. TECHNIQUE,
  128. SOUTH
    1. AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION)
  129. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT,
    1. BY DRUGS, 2020–2027 (USD MILLION) 91
  130. SOUTH AMERICA TRANSIENT
  131. ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
    1. (USD MILLION) 91
  132. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET
    1. FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  133. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY HEPARINS,
    2. TABLE
  134. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY
    1. FIBRINOLYTICS,
  135. SOUTH
  136. AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
  137. SOUTH AMERICA TRANSIENT
  138. ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 93
  139. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027
    1. (USD MILLION) 93
  140. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY
    1. COUNTRY, 2020–2027 (USD MILLION) 94
  141. EUROPE TRANSIENT ISCHEMIC
  142. ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 95
    1. TABLE 95
  143. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027
    1. (USD MILLION) 95
  144. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY
    1. TREATMENT,, 2020–2027 (USD MILLION) 95
  145. EUROPE TRANSIENT
  146. ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 96
  147. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC
    1. AGENTS, 2020–2027 (USD MILLION) 96
  148. EUROPE TRANSIENT ISCHEMIC
  149. ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    1. (USD MILLION) 96
  150. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 97
    2. TABLE
  151. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  152. EUROPE TRANSIENT ISCHEMIC
  153. ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION)
  154. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027
    1. (USD MILLION) 98
  155. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY
    1. END-USER, 2020–2027 (USD MILLION) 98
  156. WESTERN EUROPE TRANSIENT
  157. ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 99
  158. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING
    1. TECHNIQUE,
  159. WESTERN
    1. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION)
  160. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT,
    1. BY DRUGS, 2020–2027 (USD MILLION) 100
  161. WESTERN EUROPE
  162. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
    1. (USD MILLION) 100
  163. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK
  164. MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    1. MILLION) 100
  165. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET
    1. FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  166. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY FIBRINOLYTICS,
  167. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE
    1. AGENTS,
  168. WESTERN
  169. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION)
  170. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER,
  171. GERMANY TRANSIENT ISCHEMIC
  172. ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 103
    1. TABLE
  173. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
  174. GERMANY TRANSIENT ISCHEMIC
    1. ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 103
    2. TABLE 119
  175. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027
    1. (USD MILLION) 104
  176. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET
    1. FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 104
  177. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS,
    1. BY ANTIPLATELETS,
    2. TABLE
  178. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  179. GERMANY TRANSIENT
  180. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    1. (USD MILLION) 105
  181. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET
    1. FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 105
  182. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027
    1. (USD MILLION) 106
  183. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET,
    1. BY END-USER, 2020–2027 (USD MILLION) 106
  184. FRANCE TRANSIENT
  185. ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 107
  186. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
  187. FRANCE TRANSIENT ISCHEMIC
    1. ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 107
    2. TABLE 130
  188. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027
    1. (USD MILLION) 108
  189. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 108
    2. TABLE
  190. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  191. FRANCE TRANSIENT
  192. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD
    1. MILLION) 109
  193. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY FIBRINOLYTICS,
  194. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE
    1. AGENTS, 2020–2027 (USD MILLION) 109
  195. FRANCE TRANSIENT
  196. ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 110
  197. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027
    1. (USD MILLION) 110
  198. U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY
    1. DIAGNOSIS, 2020–2027 (USD MILLION) 111
  199. U.K TRANSIENT
  200. ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD
    1. MILLION) 111
  201. U.K TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,,
  202. U.K TRANSIENT ISCHEMIC ATTACK
  203. MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 112
    1. TABLE
  204. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027
    1. (USD MILLION) 112
  205. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 112
  206. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  207. U.K TRANSIENT ISCHEMIC ATTACK
  208. MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION)
  209. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE
    1. AGENTS, 2020–2027 (USD MILLION) 113
  210. U.K TRANSIENT ISCHEMIC
  211. ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 114
    1. TABLE
  212. U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION)
  213. ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027
    1. (USD MILLION) 115
  214. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 115
    2. TABLE
  215. ITALY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION)
  216. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY
    1. DRUGS, 2020–2027 (USD MILLION) 116
  217. ITALY TRANSIENT ISCHEMIC
  218. ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION)
  219. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY ANTIPLATELETS,
  220. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY
    1. HEPARINS, 2020–2027 (USD MILLION) 117
  221. ITALY TRANSIENT
  222. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    1. (USD MILLION) 117
  223. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 117
    2. TABLE
  224. ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION)
  225. ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027
    1. (USD MILLION) 118
  226. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY
    1. DIAGNOSIS, 2020–2027 (USD MILLION) 119
  227. SPAIN TRANSIENT
  228. ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD
    1. MILLION) 119
  229. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,,
  230. SPAIN TRANSIENT ISCHEMIC
  231. ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 120
  232. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC
    1. AGENTS, 2020–2027 (USD MILLION) 120
  233. SPAIN TRANSIENT ISCHEMIC
  234. ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    1. (USD MILLION) 120
  235. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR
    1. ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 121
    2. TABLE
  236. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  237. SPAIN TRANSIENT ISCHEMIC
  238. ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION)
  239. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027
    1. (USD MILLION) 122
  240. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY
    1. END-USER, 2020–2027 (USD MILLION) 122
  241. REST OF WESTERN
  242. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION)
  243. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET
    1. FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
  244. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,
  245. REST OF WESTERN EUROPE TRANSIENT
  246. ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 124
  247. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS,
    1. BY ANTITHROMBOTIC AGENTS,
  248. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY ANTIPLATELETS,
  249. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC
    1. AGENTS, BY HEPARINS,
    2. TABLE
  250. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS,
    1. BY FIBRINOLYTICS,
    2. TABLE
  251. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE
    1. AGENTS,
  252. REST OF
  253. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD
    1. MILLION) 126
  254. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK
  255. MARKET, BY END-USER, 2020–2027 (USD MILLION) 126
  256. EASTERN
  257. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION)
  258. EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS,
    1. BY IMAGING TECHNIQUE,
    2. TABLE
  259. EASTERN EUROPE TRANSIENT ISCHE

Transient Ischemic Attack Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓